Gujarat Kidney IPO Analyzed

The Gujarat Kidney and Super Speciality IPO, which opened for bidding on December 22nd, 2025, saw a huge surge in investor interest. A total of 3.53 crore shares were bid for, significantly more than the initial offering of 1.32 crore shares. This means the IPO was subscribed 2.67 times, indicating strong demand from investors. This is a key indicator of the company’s potential.

Key Points

• IPO subscribed 2.67 times, showing strong investor interest.
• Initial offering: Up to Rs 250.8 crore of new shares.
• Money raised: Rs 100.01 crore from anchor investors.
• Investment uses: Hospitals, equipment, debt repayment, and general growth.
• Promoters hold 99.1% stake, post-IPO 71.45%.
• Company provides advanced healthcare services across Gujarat.

The company’s main goal with this IPO is to use the money raised for several important things. They plan to buy the Parekhs Hospital in Ahmedabad for about Rs 77 crore. They’ll also use some money to pay for the Ashwini Medical Centre and for a small piece of a company called Harmony Medicare.

Additionally, the company needs money for building new things in their hospitals – like robotics – and to pay off some debts. The rest of the money will be used to help the company grow and improve its services. These investments demonstrate a forward-thinking strategy for the company’s future expansion.

Before the IPO, Gujarat Kidney already raised Rs 100.01 crore from some big investors. This is called an “anchor investment.” These investors bought 87.73 million shares at a price of Rs 114 each. This pre-IPO funding provided a strong foundation for the overall IPO launch.

Gujarat Kidney provides healthcare at many different locations in Gujarat, India. They have seven hospitals and four pharmacies. They specialize in treating illnesses like kidney problems, heart problems, and broken bones, as well as more serious conditions like transplants. They’re a big player in providing healthcare services across the state.

Their income comes from different sources: the government, insurance companies, and directly from patients. In the first three months of the next year (Q1 FY2026), they made a profit of Rs 4.84 crore and earned Rs 15.26 crore in revenue. This highlights their operational effectiveness and market performance.

“Strong investor demand indicates confidence in Gujarat Kidney’s long-term growth potential and its commitment to healthcare excellence.”